PROVIVE 1% Injection
Propofol
10mg/ml
CLARIS LIFESCIENCES LIMITED
| Pack size | 20ml Glass Vial |
|---|---|
| Dispensing mode | POM |
| Source | INDIA |
| Agent | BASLE PHARMACEUTICALS COMPANY L.L.C. |
| Retail Price | 20.00 AED |
Indications
PROVIVE 1% Injection is used for:
General anaesthesia, Sedation
Adult Dose
Intravenous
Induction and maintenance of general anaesthesia
Adult: Induction: 40 mg by inj or infusion every 10 sec. Usual dose: 1.5-2.5 mg/kg. Maintenance: 4-12 mg/kg/hr or intermittent bolus inj of 20-50 mg.
Elderly: Including neurosurgical and debilitated patients: Infuse at a rate of 20 mg every 10 sec. Maintenance: 3-6 mg/kg/hr. Usual dose needed: 1-1.5 mg/kg.
Sedation
Adult: In diagnostic and surgical procedures: Initially, 6-9 mg/kg/hr by infusion given for 3-5 minutes or an alternative dose of 0.5-1 mg/kg by slow inj over 1-5 minutes. Maintenance: 1.5-4.5 mg/kg/hr infusion. Reduce maintenance dose by 20% for high-risk patients needing sedation.
For ventilated patients: 0.3-4 mg/kg/hr by infusion. Monitor lipid concentrations if duration of sedation lasts >3 days.
Child Dose
Intravenous
Anesthesia
Induction
3-16 years: 2.5-3.5 mg/kg IVP over 20-30 sec
Maintenance
2 months to 16 years: 0.125-0.3 mg/kg/min IV
Renal Dose
Administration
Contra Indications
Electroconvulsive therapy, obstetrics. Sedation in children <16 yr. Pregnancy, lactation.
Precautions
Paediatrics, elderly, hypovolaemia, epilepsy, lipid disorders, patients with increased intracranial pressure. Avoid rapid bolus doses in high risk patients. Emulsion formulation of propofol 2% should only be used in children >3 yr.
Lactation: Excreted in breast milk; effect on nursing infant not known
Pregnancy-Lactation
Pregnancy category: B
Lactation: Excreted in breast milk; effect on nursing infant not known
Interactions
Reduce dose if given with nitrous oxide or halogenated anaesthetics. Increased sedative, anaesthetic and cardiorespiratory effects when used with other CNS depressants.
Adverse Effects
Side effects of Propofol :
>10%
Hypotension (peds 17%; adults 3-26%), Apnea lasting 30-60 sec (peds 10%; adults 24%), Apnea lasting >60 sec (peds 5%; adults 12%), Movement (peds 17%; adults 3-10%), Injection site burning/stinging/pain (peds 10%; adults 18%)
1-10%
Respiratory acidosis during weaning (3-10%), Hypertriglyceridemia (3-10%), Hypertension (peds 8%), Rash (peds 5%; adults 1-3%), Pruritus (1-3%), Arrhythmia (1-3%), Bradycardia (1-3%), Cardiac output decreased (1-3%; concurrent opioid use increases incidence).Tachycardia (1-3%)
<1%
Arterial hypotension, Anaphylaxis, Asystole, Bronchospasm, Cardiac arrest, Seizures, Opisthotic rxn, Pancreatitis, Pulmonary edema, Phlebitis, Thrombosis, Renal tubular toxicity
Potentially Fatal: Apnoea, bradycardia, hypotension, convulsions; anaphylaxis.
Mechanism of Action
Short-acting, lipophilic sedative/hypnotic; causes global CNS depression, presumably through agonist actions on GABAa receptors.
Note
PROVIVE 1% 10mg/ml Injection manufactured by CLARIS LIFESCIENCES LIMITED. Its generic name is Propofol. PROVIVE 1% is availble in United Arab Emirates.
Farmaco UAE drug index information on PROVIVE 1% Injection is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.